Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer

Whether neoadjuvant therapy confers a survival benefit in advanced prostate cancer (PCa) remains uncertain. The primary endpoints of previous retrospective and phase II clinical studies that used neoadjuvant therapy, including androgen deprivation therapy combined with new-generation androgen recept...

Full description

Bibliographic Details
Main Authors: Yongbao Wei, Ruochen Zhang, Dewen Zhong, Zhensheng Chen, Gen Chen, Minggen Yang, Le Lin, Tao Li, Liefu Ye, Lili Chen, Qingguo Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Pharmacology
Subjects:
prostate cancer
androgen deprivation therapy
apalutamide
neoadjuvant therapy
radical prostatectomy
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1284899/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1284899/full

Similar Items